◆英語タイトル:MilliporeSigma - Strategic SWOT Analysis Review
◆商品コード:SWOT20MY2149
◆発行会社(調査会社):
GlobalData
◆発行日:2019年12月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Medical Devices
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
MilliporeSigma – Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
Highlights
MilliporeSigma, formerly Sigma-Aldrich Corp, a subsidiary of Merck KGaA is a life sciences and technology company which offers biochemical and organic chemical products, kits and services. Its products and services find application in scientific research including genomic and proteomic research; diagnosis of diseases; pharmaceutical development and biotechnology sectors. The company offers its solutions to hospitals, biotechnology and pharmaceutical companies, commercial laboratories, universities, industrial companies, governmental institutions, non-profit organizations, diagnostic, and chemical and electronics companies. It operates across the Americas, Asia-Pacific, Europe, the Middle East and Africa. MilliporeSigma is headquartered in St. Louis, Missouri, the US.
MilliporeSigma Key Recent Developments
Nov 25,2019: Dana-Farber joins with leading Boston teaching hospitals and universities in announcing new center for advanced biological innovation and manufacturing
Nov 25,2019: Harvard Announces $50M Investment for Cell and Viral Vector Manufacturing Center at Greater Boston Area in Massachusetts, US
Jul 25,2019: 908 Devices poised to modernize upstream bioprocess analytics with a grant from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)
Apr 18,2019: DyNAbind now offers a fragment-based DEL kit available through MilliporeSigma
Apr 02,2019: MilliporeSigma elevates its Biocontinuum platform strategy to deliver ‘contiguous’ bioprocessing
Reasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
MilliporeSigma – Key Facts
MilliporeSigma – Key Employees
MilliporeSigma – Major Products and Services
MilliporeSigma – History
MilliporeSigma – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
MilliporeSigma – Business Description
MilliporeSigma – Strengths
MilliporeSigma – Weaknesses
MilliporeSigma – Opportunities
MilliporeSigma – Threats
MilliporeSigma – Key Competitors
Section 3 – Company’s Lifesciences Financial Deals and Alliances
MilliporeSigma, Medical Equipment, Deals By Year, 2013 to YTD 2019
MilliporeSigma, Medical Equipment, Deals By Type, 2013 to YTD 2019
MilliporeSigma, Recent Deals Summary
Section 4 – Company’s Recent Developments
Nov 25, 2019: Dana-Farber joins with leading Boston teaching hospitals and universities in announcing new center for advanced biological innovation and manufacturing
Nov 25, 2019: Harvard Announces $50M Investment for Cell and Viral Vector Manufacturing Center at Greater Boston Area in Massachusetts, US
Jul 25, 2019: 908 Devices poised to modernize upstream bioprocess analytics with a grant from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)
Apr 18, 2019: DyNAbind now offers a fragment-based DEL kit available through MilliporeSigma
Apr 02, 2019: MilliporeSigma elevates its Biocontinuum platform strategy to deliver ‘contiguous’ bioprocessing
Mar 20, 2019: Merck Opens First M Lab Collaboration Center in Europe
Mar 04, 2019: MilliporeSigma awarded Canadian CRISPR nickase patent for foundational genome-editing technology
Feb 21, 2019: New strategy improves efficiency of CRISPR-Cas9 genome editing
Feb 19, 2019: MilliporeSigma receives first U.S. patent for improved CRISPR genome-editing method
Dec 17, 2018: MilliporeSigma’s new Steritest NEO devices provide safer, more reliable, and more convenient sterility testing
Section 5 – Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
MilliporeSigma, Key Facts
MilliporeSigma, Key Employees
MilliporeSigma, Major Products and Services
MilliporeSigma, History
MilliporeSigma, Subsidiaries
MilliporeSigma, Joint Venture
MilliporeSigma, Key Competitors
MilliporeSigma, Medical Equipment, Deals By Year, 2013 to YTD 2019
MilliporeSigma, Medical Equipment, Deals By Type, 2013 to YTD 2019
MilliporeSigma, Recent Deals Summary
List of Figures
MilliporeSigma, Medical Equipment, Deals By Year, 2013 to YTD 2019
MilliporeSigma, Medical Equipment, Deals by Type, 2013 to YTD 2019